Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab-Reference-Cited by-同舟云学术

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

Published:2017-04-20 Issue:16 Volume:376 Page:1517-1526
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Ridker Paul M,Tardif Jean-Claude,Amarenco Pierre,Duggan William,Glynn Robert J.,Jukema J. Wouter,Kastelein John J.P.,Kim Albert M.,Koenig Wolfgang,Nissen Steven,Revkin James,Rose Lynda M.,Santos Raul D.,Schwartz Pamela F.,Shear Charles L.,Yunis Carla

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062

Cited by 295 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab;Pharmacological Research;2024-09

2. Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia;Nutrition, Metabolism and Cardiovascular Diseases;2024-09

3. PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis;Frontiers in Cardiovascular Medicine;2024-07-08

4. Research Hotspots and Development Trends on Apolipoprotein B in the Field of Atherosclerosis: A Bibliometric Analysis;Molecular Biotechnology;2024-07-04

5. Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies;mAbs;2024-06-06